April Cashin-Garbutt

Natural Sciences

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year.

Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.

See less

Articles from April

Medical image exchange: an interview with Willie Tillery, CEO of Accelarad

Accelarad’s team first recognized the need for the virtualization of radiology more than 10 years ago. Over the past six years, the industry has readily adopted cloud-based medical image exchanges, as evidenced by the thousands of physicians who share nearly half a billion images via Accelarad each year.

18 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Sunscreen application and skin cancer: an interview with Dr Michelle Hunt, Inner Sydney Dermatology

Unfortunately the incidence of skin cancer has risen in Australia over the past decades. From 1982 to 2007, melanoma diagnosis increased by around 50%, and in 2011, 1544 people died due to melanoma.

13 Nov 2013

Infection prevention: an interview with Dr. Robert Gorab, Chief Medical Officer, Hoag Orthopedic Institute

HOI has one of the lowest if not the lowest surgical readmission rate in the State of California. Our all-cause readmission rate is 3.3% and our joint replacement readmission was at 1.8% based on published CMS reports we received in September 2013.

12 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

The statistic that you often hear is that 95% of diets fail, but in actual fact, emerging research is now showing that it’s around 70% of diets that fail. That means that around 30% of people who are losing weight are actually keeping it off. So we’re doing better now than we were doing in the past, but there’s still work to be done.

7 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Health anxiety therapies: an interview with Professor Peter Tyrer, Imperial College, London

Health anxiety is a relatively new diagnosis and has not been adopted fully. The nearest approximation and formal classification systems is ‘illness anxiety’ as diagnosed in DSM-5, published in May 2013 (DSM-5, American Psychiatric Association, p.315).

5 Nov 2013

Biomedical testing: an interview with Ed Moriarty, General Manager of the ElectroForce Systems Group of Bose Corporation

An interview with Ed Moriarty, discussing how Bose are involved in the development of advanced testing equipment for medical devices.

4 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

April Cashin-Garbutt

Articles from April

Medical image exchange: an interview with Willie Tillery, CEO of Accelarad

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Sunscreen application and skin cancer: an interview with Dr Michelle Hunt, Inner Sydney Dermatology

Infection prevention: an interview with Dr. Robert Gorab, Chief Medical Officer, Hoag Orthopedic Institute

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Health anxiety therapies: an interview with Professor Peter Tyrer, Imperial College, London

Biomedical testing: an interview with Ed Moriarty, General Manager of the ElectroForce Systems Group of Bose Corporation

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News